MedTrace Logo

KSH01-TCRT Solid Tumors

NCT05539833 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-04-03

No results posted yet for this study

Summary

1\) Safety and efficacy of TCR-T cells in subjects with refractory/relapsed solid tumors. 2) The activation and proliferation of TCR-T cells in the subject, and the survival time.

Conditions

  • TCR-T Cells
  • Refractory Solid Tumors
  • Relapsed Solid Tumors

Interventions

DRUG

KSH01 injection

TCR-T cell injection

Sponsors & Collaborators

  • TCRx Therapeutics Co.Ltd

    lead INDUSTRY

Principal Investigators

  • Jie Ma · First Affiliated Hospital of Guangxi Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-19
Primary Completion
2025-07-31
Completion
2027-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05539833 on ClinicalTrials.gov